literature

HIV mutation literature information.

Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.

PMID: 31818716 2020 The lancet. HIV

Result: CS detected an additional 7 individuals with mutations conferring drug resistance to etravirine only (E38AV; V90IV; E138A; V179T; A98AG, V179T; V179DV; and A98G), who were wild-type at OLA codons.

Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.

PMID: 31914782 2020 AIDS research and human retroviruses

Abstract: Mutations such as M184V/I (35.4%) in NRTIs and K103N/R/S/T (25.4%), V179D/E/T/Y (18.9%), G190A/E/R/S (13.8%), and Y181C (9.2%) in NNRTIs were common among the HIV-1 URF strains relative to other mutations.

Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001-2017).

PMID: 31922125 2020 EClinicalMedicine

Table: V179F/D

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: V179D

HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.

PMID: 32045455 2020 PloS one

Result: The K103N mutation was the most common, followed by E138A/G, G190A and A98G, and then V179D/E/T and Y181C (Table 2).

Table: V179D

Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.

PMID: 32102660 2020 BMC infectious diseases

Abstract: The

Result: The NNRTI-associated DRMs detected at TF time point included G190S/C (66.7%), K101E/N/Q (52.4%), V179D/I/A/T/E (45.2%), Y181C (42.9%), K103R/N/S (42.9%), and V106 M (23.8%) (Table 1).

Table: V179D

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.

PMID: 32180823 2020 Drugs in context

Introduction: Other substitutions such as V106M, V108I, V179D, Y188H, or P236L conferred less than 10-FC against DOR.

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.

PMID: 32280691 2020 BioMed research international

Result: K103N (37.55%, 92/245) was the most frequent mutation, followed by G190A/E/K/Q/S/V (28.57%, 70/245), V179I/D/E/T (27.76%, 68/245), V106A/I/M (26.12%, 64/245), Y181C/V (18.78%, 46/245), K101E/H/P (14.69%, 36/245), Y188C/H/L (5.71%, 14/245), L100I (4.08%, 10/245), and M230L (4.08%, 10/245).

Result: NNRTI-associated DRMs with extensively drug resistance such as G190A/E/K/Q/S/V, V179I/D/E/T, Y18

Genetic Diversity and Drug Resistance of HIV-1 CRF55_01B in Guangdong, China.

PMID: 32294040 2020 Current HIV research

Abstract: CRF55_01B has a high primary drug resistance presence and the V179E/D mutation may confer more vulnerability to drug resistance.

Abstract: The V179E/D mutation, responsible for 100% potential low-level drug resistance, was found in all CRF55_01B sequences.

Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia.

PMID: 33285702 2020 Medicine

Abstract: Mutations associated with antiretroviral drugs include (V82A+I84IV), (L10F+Q58E), (L10F+V82Y), L10FV, L33LF, L89LMV, M184V, E138A, V106I, and V179VD.

Discussion: The E138A, conferring resistance to Rilpivirine, and Etravirine, V179VD confers resistance to Efavirenz, Etravirine, Nevirapine, and Rilpivirine, while V106I confers resistance to Etravirine, Nevirapine, Rilpivirine, and Doravirine.|m

Browser Board

Co-occurred Entities

Filtrator